TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33170131

Group type: EXPERIMENTAL
Intervention: Smartphone app (SB Colonoscopy Prep)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Written instructions
Number of subjects: 46
Study: 33170310

Group type: EXPERIMENTAL
Intervention: Cafedrine/Theodrenaline (C/T)
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Ephedrine (E)
Number of subjects: 1496
Study: 33170484

Group type: EXPERIMENTAL
Intervention: Pimasertib (dose range 1-255 mg/day)
Number of subjects: 180
Study: 33170486

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arachidonic acid (AA)
Number of subjects: 0
Study: 33170593

Group type: EXPERIMENTAL
Intervention: Transcriptional analysis of human metastatic uveal melanoma from tumor samples collected in a prospective phase II trial (A091201)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcriptional data analysis suggesting PI3K/mTOR and glycolysis pathways
Number of subjects: 0
Study: 33171129

Group type: EXPERIMENTAL
Intervention: Overground ambulation training using a powered exoskeleton (ReWalk) for 40 sessions, 3 times per week, each session lasting up to 2 hours.
Number of subjects: 8
Study: 33171144

Group type: EXPERIMENTAL
Intervention: Sex-chromosome gene content and regulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging studies
Number of subjects: 0
Study: 33171487

Group type: EXPERIMENTAL
Intervention: Oral 5-azacytidine 300 mg once per day on days 1 to 14 and romidepsin 14 mg/m2 on days 8, 15, and 22 every 35 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral 5-azacytidine and romidepsin
Number of subjects: 25
Study: 33171854

Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repeated seasonal influenza vaccination
Number of subjects: 20
Study: 33172323

Group type: EXPERIMENTAL
Intervention: Pasotuxizumab
Number of subjects: 0
Study: 33172424

Group type: EXPERIMENTAL
Intervention: NTM-PD diagnosis
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: NTM-PD treatment (antibiotics)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: CT scan changes
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Bronchiectasis Severity Index (BSI)
Number of subjects: 221
Study: 33172444

Group type: EXPERIMENTAL
Intervention: Multivariable prediction model based on 8 variables (age, race, insurance, GINI income inequality, long-term anticoagulant use, receipt of a flu vaccine in the past year, frequency of missed clinic appointments, and clinic site)
Number of subjects: 1596
Study: 33172772

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 103
Study: 33172881

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus gemcitabine and oxaliplatin (GEMOX)
Number of subjects: 38
Study: 33172887

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody testing
Number of subjects: 992
Study: 33172948

Group type: EXPERIMENTAL
Intervention: Fluid biomarkers (plasma/microdialysate neurofilament light)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Neuroimaging biomarkers (diffusion tensor MRI)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Clinical, cognitive and functional outcome measures
Number of subjects: 250
Study: 33173161

Group type: EXPERIMENTAL
Intervention: Low-dose ruxolitinib plus steroid
Number of subjects: 0
Study: 33173916

Group type: EXPERIMENTAL
Intervention: Centhaquine (0.01 mg/kg) in 100 mL normal saline infusion over 1 hour
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (normal saline) in 100 mL infusion over 1 hour
Number of subjects: 105
Study: 33174185

Group type: EXPERIMENTAL
Intervention: Metabolomics as a diagnostic tool
Number of subjects: 0
Study: 33174479

Group type: EXPERIMENTAL
Intervention: JAK1 expression in vitiligo patients' skin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: JAK3 expression in vitiligo patients' skin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: JAK2 expression in vitiligo patients' skin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation of JAK1 and JAK3 expression levels with disease activity and severity
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selective JAK3/1 inhibition
Number of subjects: 24
Study: 33175184

Group type: EXPERIMENTAL
Intervention: BPD/(VI+TOD) ratio
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: MDI score
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: PDI score
Number of subjects: 482
Study: 33175262

Group type: EXPERIMENTAL
Intervention: Multivisceral resection (MVR)
Number of subjects: 58
Study: 33175338

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 16
Study: 33175411

Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 1729
Study: 33175470

Group type: EXPERIMENTAL
Intervention: Moderated Nonlinear Factor Analysis (MNLFA) scale scoring
Number of subjects: 450

Group type: COMPARATOR
Intervention: Symptom counts
Number of subjects: 450
Study: 33175694

Group type: EXPERIMENTAL
Intervention: Digital infographic intervention designed to increase trust in science
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo-control
Number of subjects: 1000
Study: 33175860

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) method
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water perfused manometry
Number of subjects: 15
Study: 33175877

Group type: EXPERIMENTAL
Intervention: Healthcare professionals performing procedures that generated aerosols
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Healthcare professionals in emergency department and primary care units
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Healthcare professionals in public institutions
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Overall healthcare professionals
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Specific PPE shortages
Number of subjects: 1082
Study: 33175911

Group type: EXPERIMENTAL
Intervention: Minimally invasive autopsy (MIA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Histopathology
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Radiology
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Microbiology
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clinical review
Number of subjects: 18
Study: 33176023

Group type: EXPERIMENTAL
Intervention: Primary care consultations
Number of subjects: 411931

Group type: EXPERIMENTAL
Intervention: Specialist referrals
Number of subjects: 411931

Group type: EXPERIMENTAL
Intervention: Emollient prescribing
Number of subjects: 411931

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid prescribing
Number of subjects: 411931

Group type: EXPERIMENTAL
Intervention: Treatment escalation
Number of subjects: 411931
Study: 33176074

Group type: EXPERIMENTAL
Intervention: Subanesthetic intravenous ketamine combined with prolonged exposure therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33176443

Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil, dosage and duration not available
Number of subjects: 0
Study: 33176546

Group type: EXPERIMENTAL
Intervention: Surgery on Monday to Wednesday
Number of subjects: 10576

Group type: COMPARATOR
Intervention: Surgery on Thursday and Friday
Number of subjects: 10576

Group type: EXPERIMENTAL
Intervention: Patients with ≥ 6 points risk score
Number of subjects: 10576

Group type: EXPERIMENTAL
Intervention: Patients with < 6 points risk score
Number of subjects: 10576

Group type: EXPERIMENTAL
Intervention: High-risk patients (≥ 6 points) on Thursdays or Fridays
Number of subjects: 10576
Study: 33176617

Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline, metronidazole), 3 capsules every 6 hours for 10 days
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy (first-line treatment)
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy (second-line treatment)
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy (third to sixth line treatment)
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy
Number of subjects: 2100
Study: 33176718

Group type: EXPERIMENTAL
Intervention: Adolescents aged 10-19 years
Number of subjects: 11501

Group type: COMPARATOR
Intervention: Women aged 20-24 years (control group)
Number of subjects: 11501

Group type: EXPERIMENTAL
Intervention: Advanced maternal age
Number of subjects: 11501
Study: 33176736

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 73

Group type: COMPARATOR
Intervention: Normotension
Number of subjects: 73
Study: 33177132

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes, lung function, imaging and laboratory tests
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Survival analysis using the Kaplan-Meier method
Number of subjects: 800
Study: 33177139

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MI) for fibromyalgia syndrome
Number of subjects: 0
Study: 33177142

Group type: EXPERIMENTAL
Intervention: Potentially avoidable readmission within 30 days of discharge from index hospitalization.
Number of subjects: 1150
Study: 33177223

Group type: EXPERIMENTAL
Intervention: Impaired body orientation (lateropulsion)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Balance and gait rehabilitation techniques
Number of subjects: 220
Study: 33177887

Group type: EXPERIMENTAL
Intervention: 3D Sonohysterography (3D SHG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D Sonohysterography (2D SHG)
Number of subjects: 0
Study: 33177997

Group type: EXPERIMENTAL
Intervention: Lumbosacral spinal cord epidural stimulation (CV-scES) applied for 97 sessions
Number of subjects: 1
Study: 33178207

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific T-cell polyfunctionality assessment against Spike and Nucleoprotein SARS-CoV-2 peptides for 5 patients.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Monitoring of lymphocyte subsets and total monocyte and subsets counts, and HLA-DR expression.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Observation of lymphopenia, monocyte numbers, and HLA-DR expression over time.
Number of subjects: 15
Study: 33178384

Group type: EXPERIMENTAL
Intervention: 15% Lactic Acid and Ceramides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33178408

Group type: EXPERIMENTAL
Intervention: Ravulizumab every 8 weeks (q8w)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Eculizumab followed by Ravulizumab
Number of subjects: 243
Study: 33178447

Group type: EXPERIMENTAL
Intervention: Institution-based exercise plus self-management (SM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-management (SM) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33178452

Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery in patients with NPDR
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (age-matched nondiabetic patients)
Number of subjects: 23
Study: 33178636

Group type: EXPERIMENTAL
Intervention: E6011 (humanized anti-FKN monoclonal antibody)
Number of subjects: 0
Study: 33178765

Group type: EXPERIMENTAL
Intervention: Apatinib combined with paclitaxel (PTX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apatinib combined with POF (PTX, oxaliplatin, and 5-fluorouracil)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 20
Study: 33178783

Group type: EXPERIMENTAL
Intervention: Invasive ventilation practices
Number of subjects: 100000
Study: 33179149

Group type: EXPERIMENTAL
Intervention: CE-CT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 34
Study: 33179341

Group type: EXPERIMENTAL
Intervention: Eczema incidence in infants younger than 1 year
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema incidence in adults aged 40-49
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema incidence in people 80 years or older
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema prevalence in children aged 2
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema prevalence in adults aged 30-39
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema incidence in male infants (<2) and male adults older than 70
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema incidence in females for all other ages
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema incidence by ethnicity
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema incidence by socio-economic status
Number of subjects: 3850000

Group type: EXPERIMENTAL
Intervention: Eczema incidence and prevalence by geography
Number of subjects: 3850000
Study: 33179591

Group type: EXPERIMENTAL
Intervention: Solriamfetol 75, 150, or 300 mg/day for ≤ 52 weeks
Number of subjects: 333
Study: 33179845

Group type: EXPERIMENTAL
Intervention: Long-acting glucagon-like peptide-1 receptor agonists (LA GLP-1RAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DMC model
Number of subjects: 0
Study: 33180023

Group type: EXPERIMENTAL
Intervention: Wearable device (activity tracker device, Garmin vívoactive 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline assessment and follow-up assessments
Number of subjects: 0
Study: 33180026

Group type: EXPERIMENTAL
Intervention: REMOTION + psychotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Psychotherapy alone (treatment-as-usual)
Number of subjects: 70
Study: 33180106

Group type: EXPERIMENTAL
Intervention: Discontinuation of TKIs
Number of subjects: 172

Group type: COMPARATOR
Intervention: Restarting a TKI
Number of subjects: 172
Study: 33180174

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 80
Study: 33180550

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33180905

Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure Monitoring (ABPM)
Number of subjects: 52
Study: 33181648

Group type: EXPERIMENTAL
Intervention: Gastrointestinal microbiota composition analysis in fetuses with FGR
Number of subjects: 126

Group type: COMPARATOR
Intervention: Gastrointestinal microbiota composition analysis in fetuses with appropriate growth
Number of subjects: 126
Study: 33181832

Group type: EXPERIMENTAL
Intervention: Combination of ibrutinib, obinutuzumab, and venetoclax (venetoclax at 400 mg per day).
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of ibrutinib, obinutuzumab, and venetoclax.
Number of subjects: 48
Study: 33183159

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33183312

Group type: EXPERIMENTAL
Intervention: Children with CHD
Number of subjects: 124

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Parents of children with CHD
Number of subjects: 124
Study: 33183322

Group type: EXPERIMENTAL
Intervention: Increased CSF levels of ficolin-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased CSF levels of MBL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF levels of ficolin-1 and MBL in patients who developed DCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF levels of ficolin-2 and ficolin-3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma ficolin-1 and ficolin-3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DCI and functional outcome
Number of subjects: 0
Study: 33183506

Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PPCI) in 2020 during the COVID-19 pandemic
Number of subjects: 6609

Group type: EXPERIMENTAL
Intervention: Patients with arterial hypertension
Number of subjects: 6609

Group type: EXPERIMENTAL
Intervention: Door-to-balloon and total ischemia times during the pandemic
Number of subjects: 6609

Group type: EXPERIMENTAL
Intervention: Overall treatment impact during the pandemic
Number of subjects: 6609
Study: 33183563

Group type: EXPERIMENTAL
Intervention: Diverting ileostomy group (n = 41)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (n = 37)
Number of subjects: 78
Study: 33183568

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Spontaneous protein intake post-surgery
Number of subjects: 21
Study: 33184050

Group type: EXPERIMENTAL
Intervention: RhoC-derived 20mer peptide vaccine (0.1 mg, subcutaneous injections every 2 weeks for the first 6 doses, then every 4 weeks for a total of 30 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: RhoC-derived 20mer peptide vaccine
Number of subjects: 22
Study: 33184069

Group type: EXPERIMENTAL
Intervention: Clot burden score (smaller clots)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: FLAIR vascular hyperintensity score (better collaterals)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Interaction of clot burden score and FLAIR vascular hyperintensity score
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: FLAIR vascular hyperintensity score as a prognostic factor
Number of subjects: 326
Study: 33184081

Group type: EXPERIMENTAL
Intervention: Vitamin D status assessment
Number of subjects: 0
Study: 33184088

Group type: EXPERIMENTAL
Intervention: RECAP-V0 early warning score
Number of subjects: 162
Study: 33184120

Group type: EXPERIMENTAL
Intervention: Nebulised saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33184150

Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 24
Study: 33184152

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPX) on a cycle ergometer in individuals with type 1 diabetes
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control participants without type 1 diabetes
Number of subjects: 303
Study: 33184230

Group type: EXPERIMENTAL
Intervention: Endothelial microvesicles (EMV)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Leukocyte-derived microvesicles (LMV)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Platelet-derived microvesicles (PMV)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Monocytic microvesicles (MMV)
Number of subjects: 571
Study: 33184420

Group type: EXPERIMENTAL
Intervention: High resolution anorectal manometry (HRAM)
Number of subjects: 25
Study: 33184685

Group type: EXPERIMENTAL
Intervention: Bi-phasic, biodegradable, and cell-free aragonite-based scaffold (Agili-C™)
Number of subjects: 20
Study: 33184967

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 138
Study: 33185490

Group type: EXPERIMENTAL
Intervention: Hybrid technique with a novel device for microtia repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temporoparietal fascia over polypropylene implants
Number of subjects: 0
Study: 33186055

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with troponin levels under the upper limit of normal
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with troponin levels >10 times the upper limit of normal
Number of subjects: 243

Group type: COMPARATOR
Intervention: COVID-19 patients
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Clinical factors associated with myocardial injury
Number of subjects: 243
Study: 33186201

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) program, 10, 1-min high-intensity cycling intervals interspersed with 1-min recovery intervals, performed 3 days/week for 6 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual-care supervised exercise program
Number of subjects: 30
Study: 33186237

Group type: EXPERIMENTAL
Intervention: Edoxaban administered via PEG
Number of subjects: 12
Study: 33186310

Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre (LRM) with continuous inspiratory pressure of 25 cmH2O for 20 seconds
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre (LRM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Respiratory variation of pulse oximetry photoplethysmographic waveform and pulse pressure variation
Number of subjects: 30
Study: 33186471

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing investigating 740 hotspot somatic mutations in 46 genes involved in carcinogenesis.
Number of subjects: 347
Study: 33186517

Group type: EXPERIMENTAL
Intervention: Tailored clinical practice guidelines from participating centres
Number of subjects: 1329

Group type: COMPARATOR
Intervention: NICE guidelines CG102
Number of subjects: 1329

Group type: COMPARATOR
Intervention: NICE guidelines NG51
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: London clinical practice guidelines
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Nottingham clinical practice guidelines
Number of subjects: 1329
Study: 33186617

Group type: EXPERIMENTAL
Intervention: Combined external beam radiation therapy (45 Gy in 25 fractions) and HDR brachytherapy (19 Gy in 2 fractions)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Combined external beam radiation therapy and HDR brachytherapy
Number of subjects: 129
Study: 33186669

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 2289
Study: 33186783

Group type: EXPERIMENTAL
Intervention: High Urinary Symptoms Profile (USP) score related to overactive bladder
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Severe nocturia (>2 nocturnal micturitions)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Presence of urinary incontinence
Number of subjects: 154

Group type: COMPARATOR
Intervention: Type or severity of urinary symptoms (overactivity, voiding dysfunction, stress incontinence)
Number of subjects: 154
Study: 33187477

Group type: EXPERIMENTAL
Intervention: Sedentary behavior assessment prior to surgery
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Surgery-induced rise in circulating IL-6 levels
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: HMGB1 levels measured preoperatively and at 6 and 24 hours post-surgery
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE) preoperatively and at 6 weeks and 3 months post-surgery
Number of subjects: 38
Study: 33187482

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150-200 µg daily) during preconception, pregnancy, and lactation
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150-200 µg daily)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Serum thyroid-hormone parameters in the 1st trimester of pregnancy
Number of subjects: 304